◈ Nootpedia
Compact view
Research pass: thorough Sublingual / Lozenge SKIP-FOR-NOW HIGH

LSD

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Two converging lines of evidence make this a clean SKIP for Dylan at 20: (1) the placebo-controlled microdose RCT literature (de Wit, Hutten, Szigeti, Bershad 2019) is mostly null or expectancy-driven once blinding is enforced — the Yanakieva 2018 positive signal has not held up to subsequent rigorous replication, and (2) macrodose use in a still-developing 20yo prefrontal cortex with no treatment-resistant indication is hard to justify against the Schedule I legal exposure, HPPD risk, valvulopathy theoretical concern at chronic micro use (5-HT2B partial agonism), psychosis-precipitation risk in undiagnosed family history, and dangerous interaction with lithium (seizure reports) + serotonergic drugs. Documented for completeness; not a daily nootropic and not a defensible recreational tool at this life stage. Would only revisit at age 25+, after brain maturation, with a documented clinical indication (treatment-resistant depression, end-of-life anxiety, AUD), under a DEA-licensed clinical trial or regulated psilocybin/MDMA/ketamine analog program — and even then this is not the molecule of first choice given Schedule I friction.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW HIGH

    Brain still maturing (prefrontal myelination continues to ~25; serotonergic system stabilization continues into mid-20s). Microdose RCT evidence does not support cognitive enhancement claims. Macrodose has no clinical indication. Schedule I legal exposure disproportionate. HPPD risk + psychosis precipitation risk in age window. Not a defensible nootropic for this archetype. Revisit at 25+ with documented clinical indication.

  • 30-50, executive maintenance
    NOT-RELEVANT

    for daily nootropic use. Macrodose may be defensible for treatment-resistant depression / GAD under clinical-trial framework if available. Microdose claims do not survive placebo control; cognitive enhancement narrative is not supported. Schedule I legal exposure remains.

  • 50+, mild cognitive decline
    NOT-RELEVANT

    Cardiovascular load (modest BP/HR rise) + valvulopathy theoretical + psychosis-precipitation + drug interactions in polypharmacy populations all argue against. Psilocybin-assisted therapy for late-life depression (Davis 2020 JAMA Psychiatry) is more advanced clinically than LSD-equivalent.

  • Anxiety-prone
    SKIP

    unless under MM-120 clinical trial. Mindmed Phase 2b 2024 LSD-for-GAD signal is strong, but this is a clinical-trial-only path. Self-administered LSD for anxiety is high-risk (bad trip / panic possible).

  • High athletic load, tested status
    SKIP

    Recovery / sleep disruption potential (insomnia first night common); cardiovascular load during peak. Not WADA-banned per se in most lists (psychedelics are not classical PEDs) but possession violates federal law. Not relevant for Dylan's untested status, but irrelevant either way given Schedule I.

  • Sleep-disordered
    SKIP

    Causes acute insomnia first night; chronic effects unstudied. Not therapeutically relevant.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    Not a recovery agent. The "psychedelic-assisted therapy for psychiatric recovery from chronic conditions" paradigm is real but not Dylan's situation.

  • Strength/anabolic-focused
    NOT-RELEVANT

    No anabolic axis effects.

  • Treatment-resistant depression (the most defensible use case)
    OPTIONAL-ADD

    under clinical trial supervision only. Macrodose efficacy is real but accessed through psilocybin trials more readily than LSD. For the rare patient with TRD + access to MM-120 Phase 3 GAD trial or psilocybin TRD trial, this is a defensible path. Self-administration outside clinical supervision is SKIP.

  • End-of-life anxiety (Gasser indication)
    OPTIONAL

    under clinical trial. Same logic — clinical supervision required.

  • Alcohol use disorder
    OPTIONAL

    under clinical trial / supervised paradigm. Krebs 2012 meta is the largest historical evidence base. Psilocybin trials are more advanced clinically.

  • Family history of schizophrenia / bipolar I / psychosis
    HARD CONTRAINDICATION
  • Existing valvular heart disease
    HARD CONTRAINDICATION
  • On lithium
    HARD

    CONTRAINDICATION (seizure risk).

  • Pregnancy / breastfeeding
    U

    presumed unsafe.

▸ Subjective experience (deep)

Macrodose (50-200 µg)

  • Onset 30-60 min after oral/sublingual dosing
  • Come-up 60-90 min — visual brightening, time distortion onset, body buzz, anxiety spike common
  • Peak 2-5 hr — full visual effects (closed-eye visuals, geometric patterns, breathing surfaces, color enhancement), profound shifts in self-referential processing, "ego dissolution" at higher doses (200+ µg in sensitive individuals), emotional lability, music/aesthetic enhancement
  • Plateau 5-8 hr — sustained effects, often described as the "insight" phase
  • Taper 8-12 hr — gradual return; afterglow into next 24-48 hr (improved mood, relaxation, sometimes insomnia first night)
  • Total duration 8-12 hr — substantially longer than psilocybin (4-6 hr) or MDMA (4-6 hr); single sessions consume an entire day
  • Adverse acute effects: "bad trip" possible at any dose — anxiety, paranoia, panic, dysphoria, perceptual chaos. Bad trip incidence increases with: high dose, hostile set/setting, undisclosed mental health history, naive user. Risk reduction = experienced sitter, prepared environment, low starting dose, disclosed psychiatric history, no concurrent stimulants/dissociatives.

Microdose (5-20 µg, sub-perceptual or barely-perceptual)

The whole point of a microdose is that you should NOT have a clear subjective signature. Per controlled RCT data:

  • 5 µg: Generally indistinguishable from placebo subjectively. Some pain tolerance / time perception measurable changes (Bershad 2019, Hutten 2020).
  • 10 µg: Subtle subjective shifts in some users — mild mood lift, minor attention/perception changes. Often characterized as "I feel slightly different" but not reliably distinguishable from placebo expectancy.
  • 20 µg: Threshold of perceptible effect for some users. Mild visual brightening, body buzz, time distortion. Some users report "waste of an experience" (perceptible enough to notice, not enough to enjoy or learn from). 20 µg is at the upper edge of "microdose" — above this you're in low-dose macro territory.
  • The Fadiman-protocol experience claim (improved focus/mood/creativity on dose days) is mostly not replicated under blinding. The Szigeti 2021 self-blinding study is the cleanest test and showed equivalent improvement with placebo.

The contested zone — what microdose users actually report

  • "Brighter / more colorful day, more emotionally available, easier flow at work" — subjectively common, RCT-poor
  • "Productivity boost on dose days" — Reddit/Fadiman common, RCT-poor
  • "Anxiolytic / mood-stabilizing over weeks" — popular claim, Szigeti 2021 doesn't support beyond placebo
  • "Reduced rumination" — popular, mechanistically plausible (DMN modulation), unproven in rigorous trials

Honest read: Many microdose users describe genuine subjective benefit. Whether this is pharmacology, expectancy, ritual + intentionality, or some combination is unsettled and currently leans toward "mostly expectancy + ritual" based on best-evidence trials.

▸ Tolerance + cycling deep dive
  • Acute tolerance: dramatic (tachyphylaxis). Within 1-3 days of repeated full-dose LSD administration, subjective effects flatten to near-baseline. Mechanism: rapid 5-HT2A receptor downregulation/desensitization. This is one of the most pronounced acute tolerance phenomena in psychopharmacology.
  • Cross-tolerance: Full cross-tolerance with psilocybin, mescaline, DMT (oral form), 25I-NBOMe — all classical 5-HT2A psychedelics share the receptor and the tolerance state. Limited cross-tolerance with ketamine (NMDA, different receptor), MDMA (serotonin releaser, partial overlap).
  • Recommended macrodose cycling: Minimum 1 week between sessions; clinical psychedelic-assisted therapy protocols typically use 2-4 week intervals. There is no benefit to more frequent macrodosing — the tolerance kicks in and you waste the dose.
  • Microdose cycling rationale: The Fadiman every-3-days protocol attempts to stay below the threshold where complete tachyphylaxis develops, but receptor pharmacology suggests partial downregulation begins within 24-72 hours. The protocol is empirically designed (popular tradition) more than pharmacologically optimized.
  • Reset protocol if needed: 7-14 days off after any heavy use cycle; longer if chronic microdosing.
  • Long-term tolerance / sensitization: Some users report sensitization (lower threshold dose required) over years; others report tolerance + reduced subjective effect. The receptor-level dynamics over chronic micro use are not well-characterized.
▸ Stacking deep dive

Synergistic with

  • Cannabis (THC) — popular stack; intensifies and can extend the LSD experience but also significantly increases anxiety/panic risk. Not recommended for naive users; not relevant for Dylan in any case.
  • MDMA ("candyflipping") — MDMA empathogenic + LSD psychedelic; popular underground stack. No clinical evidence base; theoretical serotonergic burden + cardiovascular load. NOT recommended.
  • Psilocybin ("hippie-flipping") — full cross-tolerance via shared 5-HT2A; combination produces something between the two phenomenologically. No advantage over either alone clinically.

Avoid stacking with

  • Lithium — DANGEROUS, hard contraindication. Multiple case reports of grand mal seizures and tonic-clonic episodes when LSD or psilocybin is taken on lithium. Mechanism speculated as serotonergic-lithium interaction lowering seizure threshold; specifics unclear. Do not combine. This is the most dangerous documented LSD drug interaction.
  • MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline at high doses) — theoretical serotonin syndrome risk + unpredictable potentiation. Standard 2-week washout in psychedelic therapy protocols.
  • SSRIs / SNRIs — blunted experience (downregulated 5-HT2A) + theoretical (low) serotonin syndrome risk. Standard 2-4 week SSRI washout in modern psychedelic therapy trials.
  • Tricyclic antidepressants — unpredictable potentiation reported.
  • Tramadol, dextromethorphan — modest serotonergic load + seizure risk additive.
  • Stimulants (amphetamines, MDMA, cocaine) — cardiovascular load additive; anxiety/panic risk additive.
  • Dissociatives (ketamine, DXM, PCP) — phenomenologically chaotic; cardiovascular load; not clinically studied; some users report severe adverse experiences.
  • Bromantane, Adamax / Semax, Selank, Cerebrolysin (Russian peptides): No published interaction data; in the absence of evidence, do not combine with macrodose. Microdose interaction unstudied.
  • Modafinil: No known direct interaction; theoretically opposes the pro-anxiolytic / introspective psychedelic state with stim-flavored arousal. Not pharmacologically dangerous but phenomenologically counterproductive. Not relevant for Dylan's stack since he is not using LSD.
  • Beta-alanine, creatine, V4 supplement core: No known interactions; irrelevant since not using LSD.

Neutral / safe co-administration

N/A — verdict is SKIP. Co-administration is not in scope for Dylan's stack.

▸ Drug interactions deep dive
Interactor Effect Magnitude Action
Lithium Lowered seizure threshold, grand mal seizure risk High (multiple case reports) CONTRAINDICATED
SSRIs / SNRIs Blunted LSD experience + (low) theoretical serotonin syndrome Moderate-high blunting Avoid; standard 2-4 wk washout in clinical protocols
MAOIs Unpredictable potentiation; theoretical serotonin syndrome Variable Avoid; 2 wk washout
Tricyclic antidepressants Reported potentiation, sometimes severe Variable Avoid
Tramadol, DXM, meperidine Serotonin + seizure risk additive Moderate Avoid
NBOMe class (sold as fake LSD) Cardiotoxicity, seizures, death Critical Reagent-test substrate
Stimulants (amph, cocaine, MDMA) Cardiovascular + anxiety load additive Moderate-high Avoid
Cannabis Intensification + anxiety potentiation Moderate Avoid in naive use
Strong CYP inhibitors Theoretical exposure increase Likely modest Caution
Lithium-like mood stabilizers (carbamazepine, valproate) Theoretical seizure-threshold or potentiation effects Unclear Caution

CYP enzymes: LSD is metabolized hepatically; CYP2D6 and CYP1A2 implicated. Genetic polymorphisms likely affect exposure, but pharmacogenomic data is thin.

Hormonal contraceptives: No documented significant interaction.

▸ Pharmacogenomics

Pharmacogenomic data on LSD is thinner than for clinical antidepressants because legal research access has been restricted for decades. Indicators:

  • CYP2D6 polymorphisms — likely affect LSD clearance + exposure; CYP2D6 PMs may have higher AUC at standard dose, but no formal CPIC-style guideline exists.
  • *CYP1A2 polymorphisms (rs762551, 1F) — possibly relevant to LSD metabolism; not characterized formally for LSD specifically.
  • 5-HT2A receptor SNPs (HTR2A — rs6311, rs6313, rs6314) — variants associated with differential receptor expression and theoretical differential psychedelic response. Limited direct data on LSD response specifically; some psilocybin response data points to HTR2A genotype effects.
  • Family history of schizophrenia / bipolar I — most clinically actionable "pharmacogenomic" gate. Even without formal genotype, family history is a near-absolute contraindication in modern clinical psychedelic trials.
  • CYP2D6 ultra-rapid metabolizers (Nordic ancestry baseline ~5-7%) — Dylan's Nordic/British ancestry profile suggests slightly elevated probability of UM status; would mean lower LSD exposure at standard dose. Not actionable for SKIP-FOR-NOW verdict.

23andMe coverage: rs6311, rs6313 are reliably reported on standard 23andMe arrays. CYP2D6 star alleles require specialty interpretation (Promethease, raw data analysis, or PGx-specific panels).

Clinical implementation status: No CPIC guideline exists for LSD pharmacogenomics. The pharmacogenomic data on classical psychedelics is generally exploratory.

▸ Sourcing deep dive

US: Schedule I federal, illegal to possess, distribute, or manufacture without DEA Schedule I research license. Possession penalties vary by state (felony in most). The legal path to LSD access in the US is through DEA-licensed research labs (university programs) or industry-sponsored clinical trials (Mindmed MM-120 Phase 3 GAD program currently enrolling 2025-2026; check ClinicalTrials.gov).

Path Vendor Cost Reliability Notes
Clinical trial enrollment Mindmed MM-120 (GAD Phase 3), other psychedelic-assisted therapy programs (psilocybin/MDMA Phase 3 are more advanced) $0 (compensated participant) HIGH (DEA-controlled, GMP material) The only legal path. Eligibility usually requires diagnosed condition (depression, GAD, AUD, end-of-life anxiety) + screening exclusions. Dylan does not meet inclusion criteria for any LSD trial as a 20yo without indication.
DEA Schedule I research license Academic researchers only N/A N/A Not an option for individuals.
International psychedelic retreats (Netherlands, Jamaica, Mexico, etc.) Truffle / mushroom retreats are typically psilocybin (legal in NL truffles, decriminalized in some places). LSD-specific retreats are rare and typically operate gray-legally. $1500-5000+ per retreat Variable Psilocybin path more accessible than LSD specifically; not relevant for SKIP verdict.
Research-chem analogs (1cP-LSD, 1V-LSD, 1B-LSD, ALD-52) Research-chem vendors in some EU jurisdictions (UK ban 2021; varies elsewhere) $50-150 per 100 µg-equivalent dose Variable; COA quality varies Legally gray in some jurisdictions; pharmacologically near-identical to LSD (prodrugs that deacetylate to LSD or analogs with similar receptor profile). Sourcing is research-chem-tier (not pharma-grade). Some jurisdictions have closed analog loopholes; legal status changes frequently.
Underground / illicit market Various $5-20 per blotter (varies by region + supply chain) LOW — content highly variable; NBOMe substitution is a known fatal-overdose risk; reagent-testing essential The traditional supply chain. Not legally defensible under any framework. NBOMe substitution risk is the single most dangerous practical issue — multiple deaths attributed to mistakenly-NBOMe blotters in the past decade.

For Dylan: none of these paths apply. Verdict is SKIP-FOR-NOW. The only legitimate path (clinical trial) requires a clinical indication he does not have. The legal exposure of any other path (federal Schedule I felony) is disproportionate to any plausible benefit at his life stage with no clinical indication.

▸ Biomarkers to track (deep)

Baseline (before starting — clinical-trial paradigm only)

  • Comprehensive psychiatric screen — personal + family history of psychosis, bipolar I, schizophrenia, schizoaffective; substance use disorder history; current depression/anxiety quantified via HAM-D, MADRS, BDI, HAM-A
  • Cardiovascular — baseline BP, HR, ECG; echocardiogram if any consideration of chronic microdose use (valvular function reference)
  • Liver function panel (LFTs) — general baseline
  • CYP2D6 + CYP1A2 genotype if 23andMe data available
  • HTR2A genotype (rs6311, rs6313) — exploratory, not actionable

During use (clinical trial only)

  • Subjective experience scales — Mystical Experience Questionnaire (MEQ-30), 11-Dimensional Altered States of Consciousness (11D-ASC), Hallucinogen Rating Scale
  • Symptom-specific scales — HAM-D, MADRS for depression; HAM-A, GAD-7 for anxiety; PCL-5 for PTSD
  • Adverse event monitoring — bad trip, persistent perceptual changes, anxiety, dysphoria
  • Cardiovascular — HR/BP during dose
  • Safety follow-up at 1 day, 1 week, 1 month, 3 months, 6 months, 12 months

Post-cycle / chronic use

  • HPPD screening — visual snow, palinopsia, persistent geometric afterimages — assessed at 1 wk, 1 mo, 3 mo
  • Echocardiogram annually if chronic microdosing (theoretical valvulopathy monitoring)
  • Mood / cognition sustained tracking
▸ Controversies / open debates Live debate

  1. The microdose efficacy collapse — the central controversy. As of 2026, the rigorous placebo-controlled microdose RCT literature (de Wit, Hutten, Bershad, Szigeti) does not support the popular claims. The popular literature (Fadiman, Reddit r/microdosing, Silicon Valley narrative) continues to claim benefits. The most charitable read is that microdose benefits are real but expectancy/ritual-mediated, and pharmacology contributes little or nothing beyond that. The least charitable read is that the microdose meme is a particularly successful placebo phenomenon. Either way, it doesn't support a "microdose for cognitive enhancement" verdict for healthy users.

  2. 5-HT2B valvulopathy at chronic microdose — real or theoretical? Mechanism is real (fenfluramine, pergolide both retired for this). Empirical confirmation in microdose users is absent. The signal is the kind that takes large populations + decades to detect. Reasonable experts disagree on the magnitude. Pragmatic implication: if microdosing chronically, baseline + annual echocardiogram is the responsible approach. Most microdosers don't do this; this gap is a real safety blind spot in the popular protocol.

  3. HPPD base rate uncertainty. Estimates vary from 0.001% to 4% depending on cohort + definition. The lower end suggests it's near-negligible; the upper end suggests any psychedelic use carries meaningful risk. This is a key parameter for personal risk-benefit analysis and it's unsettled.

  4. The brain-development question for adolescents and young adults. No controlled data on classical psychedelic use in <25yo. Mechanistically, prefrontal myelination + serotonergic stabilization continues into mid-20s. The precedent from cannabis literature (early-life heavy use → altered cognitive trajectory) and psychosis literature (adolescent drug use → elevated psychosis risk in vulnerable individuals) argues for caution. Clinical psychedelic trials universally exclude <18yo and frequently <21yo. For Dylan at 20, this is a pragmatic precautionary basis for SKIP independent of any other concern.

  5. The Schedule I question — is the legal framework rational? Most pharmacologists would say no — LSD is one of the lower-acute-toxicity recreational compounds, has demonstrated clinical efficacy for several indications, and the Schedule I framework prevents medical use that's available legally in some other jurisdictions for the same compound. But Dylan operates under US federal law, not the rational regulatory framework that should exist. Verdict respects the actual legal environment.

  6. The "trip is the medicine" vs "molecular afterglow is the medicine" debate. Macrodose psychedelic therapy trials show acute subjective experience (mystical experience scores) correlate with clinical outcome — the trip seems to matter, not just the molecule. The Olson lab (UC Davis) is pursuing non-hallucinogenic psychoplastogens (tabernanthalog, AAZ-A-154) that try to capture the BDNF/synaptogenesis effect without the hallucinations. If non-hallucinogenic psychoplastogens succeed clinically, much of the LSD use case evaporates — the molecule itself is replaceable by safer/cleaner alternatives. This is a 5-10 year development arc.

  7. Recreational vs clinical use of LSD — the false dichotomy. Much of the popular psychedelic literature treats macrodose recreational use, microdose enhancement use, and clinical psychedelic-assisted therapy as variations of the same activity. They're not. Clinical use under supervision with screening, integration psychotherapy, and indication-specific protocols is a different intervention than self-dosing at a music festival. The evidence bases don't translate cleanly between these contexts.

  8. MM-120 / Mindmed Phase 3 trajectory. Mindmed's MM-120 (LSD for GAD) received FDA Breakthrough Therapy designation in March 2024 and Phase 3 enrollment opened 2024-2025. If Phase 3 succeeds (estimated readout 2027-2028), LSD could become a legally prescribable therapeutic for the first time since 1970. This would change the regulatory picture entirely but doesn't change Dylan's verdict for now (no GAD diagnosis, not a trial candidate).

▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-FOR-NOW HIGH confidence. Two converging lines: (1) microdose RCT literature collapses popular benefit claims under placebo control (Yanakieva 2018 single-dose acute pharmacology positive, but Hutten/de Wit/Bershad/Szigeti rigorous-blind work largely null on sustained benefits — the popular Fadiman-protocol claims are mostly expectancy-driven), and (2) macrodose use in still-developing 20yo PFC + serotonergic system without clinical indication is hard to defend against Schedule I legal exposure, HPPD risk, valvulopathy theoretical concern (5-HT2B), psychosis-precipitation in age-of-onset window, and dangerous lithium interaction. Documented for completeness.
  • Would revisit at:
    • Age 25+ (post-PFC maturation)
    • Documented clinical indication (TRD, treatment-resistant GAD, AUD, end-of-life anxiety)
    • Access to DEA-licensed clinical trial (Mindmed MM-120 Phase 3 if Dylan develops GAD; psilocybin TRD trials more available)
    • Even then, this is unlikely to be the molecule of first choice — psilocybin and ketamine have more advanced clinical infrastructure; non-hallucinogenic psychoplastogens (tabernanthalog) may be available by then.
▸ Open questions / gaps Open
  1. Long-term microdose safety — chronic 5-HT2B exposure + valvulopathy: low-base-rate signal, takes decades to confirm or refute. No clinical monitoring guideline exists.
  2. Brain-development effects in <25yo — no controlled data; mechanistic precaution argues for SKIP.
  3. Whether non-hallucinogenic psychoplastogens (tabernanthalog, 2-Br-LSD, AAZ-A-154) succeed clinically — would deprecate LSD itself.
  4. MM-120 Phase 3 outcome — if positive (2027-2028 readout), LSD becomes a legitimate Rx therapy for GAD; current SKIP for Dylan still applies in absence of GAD diagnosis.
  5. HPPD true incidence — base rate uncertainty is a major personal-risk-assessment limitation.
  6. Microdose mechanism — is there any pharmacological signal beyond placebo + ritual? Cameron 2019 suggests yes in rodents; human RCTs say not at clinically meaningful levels for the popular benefit claims.
  7. 5-HT2A SNP × LSD response — possible responder/non-responder stratification but unstudied at scale.

What would change the verdict: (a) Dylan ages to 25+ AND develops clinical indication (TRD, GAD, AUD, end-of-life context), AND (b) clinical trial access exists, AND (c) baseline biomarkers (echocardiogram, family-history-screening, cardiovascular workup, no contraindicated medications) are clean. Even then, psilocybin / ketamine / non-hallucinogenic psychoplastogens are more likely to be the right tools for those indications than LSD specifically.

▸ Sources (full, with our context)
Back to compact view